Bristol-Myers Squibb Reports First Quarter Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers (BMY) Bullish Stance Reiterated at BMO Capital Post Q1 and Ahead of ASCO Inflection for Opdivo

April 29, 2015 9:01 AM EDT

BMO Capital analyst Alex Arfaei reiterated an Outperform rating and $75 on Bristol-Myers Squibb Co. (NYSE: BMY) following Q1 results and as ASCO should be an inflection point for Opdivo.

commented, "On the surface, 1Q looked solid: 6% topline beat, EPS $0.71 vs. $0.51. However, the Abilify beat is short-lived, and focus remains on the IO franchise. As we expected Yervoy sales were 6% below consensus, probably reflecting increased competition, and Opdivo sales... More

Bristol-Myers Squibb (BMY) Tops Q1 EPS by 20c; Adjusts FY15 EPS Outlook

April 28, 2015 7:31 AM EDT

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $0.71, $0.20 better than the analyst estimate of $0.51. Revenue for the quarter came in at $4.04 billion versus the consensus estimate of $3.8 billion.

Bristol-Myers Squibb sees FY2015 adjusted EPS from $1.55-$1.70 to $1.60-$1.70, versus the consensus of... More